Traders Purchase Large Volume of Zura Bio Call Options (NASDAQ:ZURA)

Posted by George Bondi on Nov 12th, 2026

Zura Bio Limited (NASDAQ:ZURA – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Traders purchased 3,037 call options on the company. This is an increase of approximately 57% compared to the average daily volume of 1,935 call options.

Institutional Trading of Zura Bio

Institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Zura Bio by 3.4% during the first quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock worth $1,864,000 after acquiring an additional 10,200 shares during the period. Ethic Inc. bought a new position in Zura Bio in the 3rd quarter valued at $53,000. Dimensional Fund Advisors LP increased its position in shares of Zura Bio by 83.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 43,135 shares of the company’s stock valued at $257,000 after purchasing an additional 19,603 shares during the last quarter. Alps Advisors Inc. increased its position in shares of Zura Bio by 30.7% during the 3rd quarter. Alps Advisors Inc. now owns 126,053 shares of the company’s stock valued at $524,000 after purchasing an additional 29,639 shares during the last quarter. Finally, ADAR1 Capital Management LLC increased its position in shares of Zura Bio by 12.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 630,403 shares of the company’s stock valued at $3,751,000 after purchasing an additional 68,338 shares during the last quarter. Institutional investors own 61.14% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on ZURA shares. Oppenheimer reduced their price target on shares of Zura Bio to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday. Guggenheim restated a “buy” rating on shares of Zura Bio in a research report on Friday, October 30th. Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Wedbush upped their target price on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings raised Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.50.

Read Our Latest Stock Report on Zura Bio

Zura Bio Trading Up 1.8%

Shares of ZURA opened at $1.43 on Thursday. The firm’s fifty day simple moving average is $4.20 and its two-hundred day simple moving average is $5.13. Zura Bio has a 12 month low of $0.93 and a 12 month high of $7.44. The stock has a market capitalization of $137.74 million, a P/E ratio of -1.28 and a beta of 0.03.

Zura Bio (NASDAQ:ZURA – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) EPS for the quarter, hitting analysts’ consensus estimates of ($0.20). As a group, research analysts predict that Zura Bio will post -0.82 EPS for the current fiscal year.

Key Zura Bio News

Investors following ZURA have been watching these news items:

Neutral Sentiment: Oppenheimer kept its “outperform” rating but cut its price target to $5 from $16. The lower target reflects reduced expectations, although it remains above the cited share price. Oppenheimer Adjusts Price Target on Zura Bio to $5 From $16, Maintains Outperform Rating
Neutral Sentiment: Zura Bio is scheduled to report earnings Thursday; the announcement may provide updates on its finances and pipeline following the trial setback. Zura Bio (ZURA) Set to Release Earnings on Thursday
Negative Sentiment: Law firms announced shareholder investigations into potential securities claims involving Zura Bio. These are investigations, not findings of wrongdoing, but may add uncertainty and reputational pressure. ZURA shareholder investigation

Zura Bio Company Profile

(Get Free Report)

Zura Bio is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. Its research targets immune pathways that may contribute to a range of chronic conditions. The company’s investigational pipeline includes tibulizumab (ZB-106), a dual-targeting antibody designed to inhibit BAFF and IL-17A, and ZB-168, an antibody targeting the IL-7 receptor alpha. These candidates are being developed for potential use in autoimmune and inflammatory conditions.